Budesonide

Generic Name: Budesonide

Brand Names: Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₄O_₆

CAS Number: 51333-22-3

Unique Ingredient Identifier: Q3OKS62Q6X

Background: Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.

Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.

Indication: Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. Extended-release capsules are indicated to induce remission of mild to moderate ulcerative colitis and a rectal foam is used for mild to moderate distal ulcerative colitis. In addition, a delayed-release capsule formulation of budesonide is indicated to reduce proteinuria in adults with IgA nephropathy at risk of rapid disease progression. In Europe, budesonide is indicated to treat eosinophilic esophagitis (EoE) in adults.

Associated Conditions: Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease

Associated Therapies: Maintenance therapy

Clinical Trials

The Effect of Oral Polymeric Diet Enriched With TGF-beta 2 (Modulen) on Clinical Response and Mucosal Healing in Adult Patients With Newly Diagnosed Crohn's Disease

Not Applicable

Conditions: Crohn Disease

Interventions: Dietary Supplement: Modulen
Drug: Budesonide

First Posted Date: 2020-01-18

Last Posted Date: 2020-01-18

Lead Sponsor: Hillel Yaffe Medical Center

Target Recruit Count: 50

Registration Number: NCT04233463

Locations: 🇮🇱
Hillel Yaffe Medical Center, Hadera, Israel

As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder
Drug: Budesonide 200Mcg Inhalation Powder

First Posted Date: 2020-01-02

Last Posted Date: 2022-08-03

Lead Sponsor: Hat Yai Medical Education Center

Target Recruit Count: 31

Registration Number: NCT04215848

Locations: 🇹🇭
Hatyai Hospital, Hat Yai, Songkhla, Thailand

ARrest RESpiraTory Failure From PNEUMONIA

Phase 3

Recruiting

Conditions: Acute Respiratory Failure
Pneumonia
Hypoxemia
COVID-19 Pneumonia

Interventions: Drug: Inhaled placebo
Drug: Inhaled budesonide and formoterol

First Posted Date: 2019-12-10

Last Posted Date: 2024-07-12

Lead Sponsor: Stanford University

Target Recruit Count: 600

Registration Number: NCT04193878

Locations: 🇺🇸
University of Alabama Birmingham - Main & Highlands, Birmingham, Alabama, United States
🇺🇸
University of Arizona - Main & South Campus, Tucson, Arizona, United States
🇺🇸
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States

and more 9 locations

Efficacy and Safety of Flamboyant 200/12 Association in the Treatment of Adults With Severe Asthma

Phase 3

Conditions: Asthma

Interventions: Drug: Flamboyant 200/12
Drug: Budesonide / Formoterol 400/12
Other: Budesonide / Formoterol 400/12 Placebo
Other: Flamboyant 200/12 Placebo

First Posted Date: 2019-12-09

Last Posted Date: 2022-07-27

Lead Sponsor: EMS

Target Recruit Count: 134

Registration Number: NCT04191447

Locations: 🇧🇷
IMC Tatuí, Tatuí, São Paulo, Brazil

Nitric Oxide Releasing Sinus Irrigation (NOSi) to Treat Recalcitrant Chronic Rhinosinusitis (RCRS)

Phase 2

Completed

Conditions: Chronic Sinusitis

Interventions: Drug: Nitric Oxide
Drug: Budesonide

First Posted Date: 2019-11-15

Last Posted Date: 2022-06-30

Lead Sponsor: Sanotize Research and Development corp.

Target Recruit Count: 56

Registration Number: NCT04163978

Locations: 🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada

A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution

Phase 4

Completed

Conditions: Rhinitis

Interventions: Other: Placebo
Drug: Budesonide

First Posted Date: 2019-10-21

Last Posted Date: 2021-01-22

Lead Sponsor: Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division

Target Recruit Count: 206

Registration Number: NCT04132570

Locations: 🇨🇳
Beijing Tongren Hospital, Cmu, Beijing, Beijing, China
🇨🇳
The No.2 Hospital of Baoding, Baoding, Hebei, China
🇨🇳
Cangzhou Center Hospital, Cangzhou, Hebei, China

and more 3 locations